Lifitegrast
Lifitegrast (pronounced li-fi-te-grast) is a medication used in the treatment of dry eye disease. It is marketed under the brand name Xiidra by Shire, a global biopharmaceutical company.
Etymology
The term "Lifitegrast" is a coined name with no specific etymology. It is a common practice in pharmaceutical naming to create unique, non-descriptive names for new medications.
Pharmacology
Lifitegrast works by blocking a protein on the surface of cells in your body. This protein is called lymphocyte function-associated antigen 1 (LFA-1). By blocking LFA-1, Lifitegrast prevents it from binding with another protein called intercellular adhesion molecule 1 (ICAM-1). This binding usually causes inflammation, which can lead to dry eye symptoms.
Usage
Lifitegrast is used to treat the signs and symptoms of dry eye disease. It is usually prescribed as one drop in each eye twice a day, 12 hours apart.
Side Effects
Common side effects of Lifitegrast include eye irritation, discomfort or blurred vision when the drops are applied to the eyes, and an unusual taste sensation.
Related Terms
- Dry eye disease
- Xiidra
- Lymphocyte function-associated antigen 1
- Intercellular adhesion molecule 1
- Inflammation
- Pharmacology
External links
- Medical encyclopedia article on Lifitegrast
- Wikipedia's article - Lifitegrast
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski